Stock data
Anavex Life Sciences Corp. (AVXL)
Anavex Life Sciences Corp. (AVXL) reported net income of -US$46.38M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-09-30
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$51.41M | -US$46.38M | — |
| 2024 | — | — | -US$52.88M | -US$43.00M | — |
| 2023 | — | — | -US$55.76M | -US$47.51M | — |
| 2022 | — | — | -US$50.99M | -US$47.98M | — |
| 2021 | — | — | -US$42.00M | -US$37.91M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | US$7.82M | — |
| 2026-03-31 | — | -US$5.34M | — |
| 2025-12-31 | — | -US$5.68M | — |
| 2025-09-30 | — | -US$9.83M | — |
| 2025-06-30 | — | -US$13.24M | — |
| 2025-03-31 | — | -US$11.20M | — |
| 2024-12-31 | — | -US$12.11M | — |
| 2024-09-30 | — | -US$11.62M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.